收费全文 | 1051236篇 |
免费 | 74572篇 |
国内免费 | 2455篇 |
耳鼻咽喉 | 14850篇 |
儿科学 | 26192篇 |
妇产科学 | 25018篇 |
基础医学 | 152008篇 |
口腔科学 | 31248篇 |
临床医学 | 91970篇 |
内科学 | 204631篇 |
皮肤病学 | 23035篇 |
神经病学 | 81937篇 |
特种医学 | 43666篇 |
外国民族医学 | 79篇 |
外科学 | 167536篇 |
综合类 | 18835篇 |
现状与发展 | 4篇 |
一般理论 | 260篇 |
预防医学 | 68261篇 |
眼科学 | 24351篇 |
药学 | 83645篇 |
3篇 | |
中国医学 | 3592篇 |
肿瘤学 | 67142篇 |
2021年 | 9855篇 |
2019年 | 8771篇 |
2018年 | 12451篇 |
2017年 | 9878篇 |
2016年 | 11507篇 |
2015年 | 14267篇 |
2014年 | 18345篇 |
2013年 | 24830篇 |
2012年 | 35013篇 |
2011年 | 35604篇 |
2010年 | 20860篇 |
2009年 | 19525篇 |
2008年 | 31878篇 |
2007年 | 32687篇 |
2006年 | 32682篇 |
2005年 | 31149篇 |
2004年 | 29545篇 |
2003年 | 27925篇 |
2002年 | 26829篇 |
2001年 | 57108篇 |
2000年 | 58753篇 |
1999年 | 48661篇 |
1998年 | 11559篇 |
1997年 | 10075篇 |
1996年 | 10064篇 |
1995年 | 9331篇 |
1994年 | 8639篇 |
1993年 | 7898篇 |
1992年 | 36107篇 |
1991年 | 34487篇 |
1990年 | 33275篇 |
1989年 | 32302篇 |
1988年 | 29385篇 |
1987年 | 28620篇 |
1986年 | 26561篇 |
1985年 | 25438篇 |
1984年 | 18051篇 |
1983年 | 15299篇 |
1982年 | 7920篇 |
1979年 | 15976篇 |
1978年 | 10735篇 |
1977年 | 9148篇 |
1976年 | 7983篇 |
1975年 | 8730篇 |
1974年 | 10584篇 |
1973年 | 9955篇 |
1972年 | 9453篇 |
1971年 | 8935篇 |
1970年 | 8494篇 |
1969年 | 7974篇 |
Objectives
To investigate whether functional overreaching affects locomotor system behaviour when running at fixed relative intensities and if any effects were associated with changes in running performance.Design
Prospective intervention study.Methods
Ten trained male runners completed three training blocks in a fixed order. Training consisted of one week of light training (baseline), two weeks of heavy training designed to induce functional overreaching, and ten days of light taper training designed to allow athletes to recover from, and adapt to, the heavy training. Locomotor behaviour, 5-km time trial performance, and subjective reports of training status (Daily Analysis of Life Demands for Athletes (DALDA) questionnaire) were assessed at the completion of each training block. Locomotor behaviour was assessed using detrended fluctuation analysis of stride intervals during running at speeds corresponding to 65% and 85% of maximum heart rate (HRmax) at baseline.Results
Time trial performance (effect size ±95% confidence interval (ES): 0.16 ± 0.06; p < 0.001), locomotor behaviour at 65% HRmax (ES: ?1.12 ± 0.95; p = 0.026), and DALDA (ES: 2.55 ± 0.80; p < 0.001) were all detrimentally affected by the heavy training. Time trial performance improved relative to baseline after the taper (ES: ?0.16 ± 0.10; p = 0.003) but locomotor behaviour at 65% HRmax (ES: ?1.18 ± 1.17; p = 0.048) and DALDA (ES: 0.92 ± 0.90; p = 0.045) remained impaired.Conclusions
Locomotor behaviour during running at 65% HRmax was impaired by functional overreaching and remained impaired after a 10-day taper, despite improved running performance. Locomotor changes may increase injury risk and should be considered within athlete monitoring programs independently of performance changes. 相似文献Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献